We have located links that may give you full text access.
Clinical Trial
Controlled Clinical Trial
Journal Article
Review
Insights on treating an over-the-counter-type subgroup: data from the Air Force/Texas Coronary Atherosclerosis Prevention Study Population.
American Journal of Cardiology 2000 June 23
The expansion of therapeutic options for management of dyslipidemia is a potentially valuable avenue for the optimal treatment of most patients at low-to-moderate risk for coronary artery disease (CAD). In primary prevention, this population is closely approximated by that of the landmark Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). In AFCAPS/TexCAPS, 6,605 men and women without evidence of CAD and with average total cholesterol (180-264 mg/dL) and low-density lipoprotein (LDL)-cholesterol (130-190 mg/dL) concentrations and low high-density lipoprotein (HDL)-cholesterol levels (< or =45 mg/dL for men, < or =47 mg/dL for women) were treated with either lovastatin or placebo for a mean of 5.2 years. With few exceptions, the characteristics of the AFCAPS/TexCAPS cohort were similar to the profile of the majority of people in the United States and that of a potential over-the-counter (OTC)-type subgroup. The dosage of lovastatin used was 20-40 mg/day, titrated to achieve an LDL-cholesterol target of < or =110 mg/dL. Treatment reduced the combined incidence of fatal and nonfatal myocardial infarction, unstable angina, and sudden cardiac death by 37% (p<0.001). The risk for fatal and nonfatal heart attack was reduced by 40% (p<0.002), and the need for coronary revascularization procedures was reduced by 33% (p = 0.01). Post hoc analysis of data from a subgroup of the AFCAPS/TexCAPS cohort resembling those in the general population who may benefit from OTC statins indicates similar benefits. The results have important implications for the identification and treatment of persons at risk for coronary disease.
Full text links
Related Resources
Trending Papers
Executive Summary: State-of-the-Art Review: Unintended Consequences: Risk of Opportunistic Infections Associated with Long-term Glucocorticoid Therapies in Adults.Clinical Infectious Diseases 2024 April 11
Autoimmune Hemolytic Anemias: Classifications, Pathophysiology, Diagnoses and Management.International Journal of Molecular Sciences 2024 April 13
Clinical practice guidelines on the management of status epilepticus in adults: A systematic review.Epilepsia 2024 April 13
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app